Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03382977 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
A Phase 1 study of Glioblastoma Multiforme, sponsored by VBI Vaccines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
- 12
- Study locations
NCT03382977 is a Phase 1 study of Glioblastoma Multiforme that is actively recruiting participants, run by VBI Vaccines. The registered enrollment target is 98 participants, roughly in line with the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target. The trial reports 12 study locations across 8 states.
The verdict
NCT03382977, a Phase 1 study of Glioblastoma Multiforme, is actively recruiting participants, sponsored by VBI Vaccines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
Conditions Studied
Interventions
- BIOLOGICAL VBI-1901
- DRUG Carmustine
- DRUG Lomustine
Study Locations (12)
California
- University of California, Irvine - Irvine
- University of California, San Diego - La Jolla
- University of California, Los Angeles Neuro-Oncology Program - Los Angeles
- Stanford - Stanford
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Florida
- Miami Cancer Institute - Miami
New Jersey
- The Valley Hospital - Neurosurgeons of New Jersey - Ridgewood
New York
- The Neurological Institute of New York Columbia University Medical Center - New York
Tennessee
- Vanderbilt University Medical Center - Nashville
Texas
- MD Anderson Cancer Center - Houston
Washington
- Providence - Swedish Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2017-12-06 |
| Est. Completion | 2025-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03382977
The ClinicalTrials.gov registry entry for NCT03382977 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target. The listed sponsor is VBI Vaccines, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 3 interventions - of which VBI-1901 is the first listed.
NCT03382977 reports 12 study locations spanning 8 distinct geographic areas - top geographies include California, Massachusetts, Florida.
Frequently Asked Questions
What is clinical trial NCT03382977 about?
NCT03382977 is a clinical study titled "Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects". The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
What is the current status of trial NCT03382977?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2017-12-06. Estimated completion is 2025-08.
What conditions does trial NCT03382977 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT03382977?
The interventions under investigation include: VBI-1901 (BIOLOGICAL), Carmustine (DRUG), Lomustine (DRUG).
Who is sponsoring clinical trial NCT03382977?
This trial is sponsored by VBI Vaccines, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03382977 being conducted?
This trial has 12 study locations across California, Florida, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RECRUITING · Phase 1
-
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
RECRUITING · Phase 1
-
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.